FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

QS, MDR Violations at Rontis Hellas in Greece

FDA warns Greeces Rontis Hellas about Quality System and Medical Device Reporting violations in its production of a balloon catheter.

latest-news-card-1
Human Drugs

FDA Approves BMS Opdivo Qvantig Injection

FDA approves Bristol Myers Squibbs Opdivo Qvantig subcutaneous injection for several cancer indications.

latest-news-card-1
Human Drugs

FDA Approves Checkpoints Unloxcyt

FDA approves Checkpoint Therapeutics Unloxcyt to treat some squamous cell cancer patients.

latest-news-card-1
Human Drugs

CGMP Violations in Micro Orgo Chem Inspection

FDA warns Indias Micro Orgo Chem about CGMP deviations in its production of active pharmaceutical ingredients.

latest-news-card-1
Human Drugs

Guide on Drug Batch Uniformity and Integrity

FDA posts a draft guidance entitled Considerations for Complying With 21 CFR 211.110 that describes how to comply with batch uniformity and drug produ...

latest-news-card-1
Federal Register

Guide on Advanced Manufacturing Tech

Federal Register notice: FDA makes available a final guidance entitled Advanced Manufacturing Technologies (AMT) Designation Program.

latest-news-card-1
Human Drugs

Chimerix NDA for Glioma Drug

Chimerix files an NDA seeking accelerated approval for dordaviprone as a treatment for patients with recurrent H3 K27M-mutant diffuse glioma.

latest-news-card-1
Federal Register

Meeting on Pediatric Drug Development/Labeling

Federal Register notice: FDA announces a 5/15 public meeting entitled Implementation of the Best Pharmaceuticals for Children Act and Pediatric Resear...

latest-news-card-1
FDA General

Temple Retires; Bumpus Leaves FDA

CDER senior advisor for clinical science Bob Temple retires, and FDA principal deputy commissioner Namandj Bumpus leaves the agency ahead of the new i...

latest-news-card-1
Biologics

Xbrane Refiles Lucentis Biosimilar BLA

Xbrane Biopharma refiles a BLA for its investigational ranibizumab, a biosimilar copy of Genentechs age-related macular degeneration drug Lucentis.